Rigel Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares, representing 8.95% of Rigel Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.
NASDAQ
Soleus Capital Master Fund, L.P. and affiliated entities have reported beneficial ownership of 9.9% of Rigel Pharmaceuticals Inc. common stock as of June 30, 2026.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,280,000 shares, representing 6.93% of Rigel Pharmaceuticals, Inc. common stock.
NASDAQ
Soleus Capital Master Fund, L.P. and affiliated entities have filed a Schedule 13G reporting a 5.2% beneficial ownership stake in Rigel Pharmaceuticals, Inc.
NASDAQ
The Vanguard Group reported a 0% beneficial ownership in Rigel Pharmaceuticals Inc. following an internal corporate realignment.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 3.99% beneficial ownership stake in Rigel Pharmaceuticals, Inc.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported ceasing to be beneficial owners of more than five percent of Rigel Pharmaceuticals Inc.'s common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an Amendment No. 5 to their Schedule 13G, reporting beneficial ownership of 8.92% of Rigel Pharmaceuticals, Inc.'s common stock.
NASDAQ
Soleus Capital Master Fund and related entities report a 3.7% beneficial ownership stake in Rigel Pharmaceuticals, Inc. as of June 30, 2025.
NASDAQ
Armistice Capital, LLC and its managing member Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.48% in Rigel Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in Rigel Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an Amendment No. 3 to Schedule 13G, disclosing a beneficial ownership of 6.54% in Rigel Pharmaceuticals, Inc. as of December 31, 2024.
NASDAQ
Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have disclosed a beneficial ownership of 6.4% in Rigel Pharmaceuticals, Inc., holding 1,130,679 shares as of December 31, 2024.
NASDAQ
Invesco Ltd. has filed an amended Schedule 13G, reporting a 0.0% beneficial ownership stake in Rigel Pharmaceuticals Inc. as of December 31, 2024.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 9.9% of Rigel Pharmaceuticals Inc.'s common stock as of December 31, 2024.